GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Price-to-Free-Cash-Flow

Epigenomics AG (Epigenomics AG) Price-to-Free-Cash-Flow : N/A (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Price-to-Free-Cash-Flow?

As of today (2024-04-28), Epigenomics AG's share price is $2.50. Epigenomics AG's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-17.13. Hence, Epigenomics AG's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Epigenomics AG's Price-to-Free-Cash-Flow or its related term are showing as below:

EPGNF's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 26.29
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Epigenomics AG's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-4.04. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-17.13.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 34.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 32.00% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 20.10% per year.

During the past 13 years, Epigenomics AG's highest 3-Year average Free Cash Flow per Share Growth Rate was 50.40% per year. The lowest was -55.90% per year. And the median was 18.25% per year.


Epigenomics AG Price-to-Free-Cash-Flow Historical Data

The historical data trend for Epigenomics AG's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Price-to-Free-Cash-Flow Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Epigenomics AG's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, Epigenomics AG's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Price-to-Free-Cash-Flow falls into.



Epigenomics AG Price-to-Free-Cash-Flow Calculation

Epigenomics AG's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.50/-17.126
=N/A

Epigenomics AG's Share Price of today is $2.50.
Epigenomics AG's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Epigenomics AG  (OTCPK:EPGNF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Epigenomics AG Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (Epigenomics AG) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines